breaking news - update

BASF sees synergies between new acquisition Pronova and Equateq

By Gareth Macdonald

- Last updated on GMT

BASF wins over Pronova shareholders
BASF wins over Pronova shareholders
BASF has had its offer for omega-3 API maker Pronova Biopharma accepted by 97.7 per cent of the Norwiegan firm’s shareholders.

The deal – which will see the German firm pay around €684m for Pronova – was finally accepted last week after a bidding process that saw the German chemicals firm increase its offer​ in response to resistance from minority shareholders.

A BASF spokesman told in-Pharmatechnologist.com today that: “We are confident that this is a good investment.

This acquisition will create numerous synergies by combining BASF’s global customer reach and many years of experience with Pronova’s solid know-how and scientific expertise in the production of highly concentrated omega-3 fatty acids, with the technology portfolio of Equateq [now operating under the name BASF Pharma Callanish]​.”

He explained that the aim of the deal was to strengthen BASF’s portfolio and expand its position in the research and development and manufacturing of omega-3 fatty acids for pharmaceutical and consumer health products.

BASF will have an attractive technology portfolio for developing and manufacturing omega-3 fatty acids. Highly concentrated omega-3 fatty acids are a globally growing market, driven by an increasing consumer awareness of omega-3 fatty acid health benefits​.”  

Pronova supplies GSK with the active pharmaceutical ingredient (API) for its heart pill Lovaza. BASF’s other omega-3 business – BASF Pharma Callanish -  is one of the firm’s for which Amarin is seeking US Food and Drug Administration (FDA) approval as a supplier for its rival product Vascepa​.

Fatty acid synergies

Pronova gives BASF capacity. The firm operates two production facilities – one in Norway and one in Denmark – which are capable of producing 2,500 tons of pharmaceutical grade omega-3 a year and employs around 311 people.

This contrasts with BASF Callanish, which has a single production facility on the Isle of Lewis in Scotland​.

The technology 'synergies' mentioned above are likely to involve the proprietary chromatographic separation methods in place at Callanish that - according to BASF​ - allow for more flexible blending and formulation of omega-3 fatty acids at exceptional purity levels.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars